Oncology & Cancer

Immunotherapy drug bolsters head and neck cancer treatment

A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.

Medications

Lenvatinib + pembrolizumab treats advanced endometrial cancer

(HealthDay)—For patients with advanced endometrial cancer, lenvatinib plus pembrolizumab results in significantly longer progression-free and overall survival than the physician's choice of chemotherapy, according to a ...

Medications

Adjuvant pembrolizumab beneficial in renal cell carcinoma

(HealthDay)—For patients with clear-cell renal cell carcinoma at high risk for recurrence after nephrectomy, adjuvant therapy with pembrolizumab improves disease-free survival, according to a study published in the Aug. ...

Oncology & Cancer

Immunotherapy drug delays recurrence in kidney cancer patients

Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy ...

page 1 from 6